Literature DB >> 21508678

Five-year post vaccination efficacy of hepatitis B vaccine in rural Nigeria.

Olumuyiwa O Odusanya1, Ewan Alufohai, François P Meurice, Vincent I Ahonkhai.   

Abstract

Hepatitis B (HB) is an important public health problem affecting millions of people globally and is endemic in Nigeria. The objective of this study was to determine the effectiveness of the HB vaccine five to seven years post-introduction within a rural community in Nigeria. The study design was cross-sectional. Eligible children were either vaccinated subjects who had received at least two doses of HB vaccine or unvaccinated subjects (controls) who had not received HB vaccine. Following informed consent obtained from mothers/care givers, data was obtained using an interviewer-administered questionnaire. Venous blood was obtained to measure HB markers including hepatitis B surface antigen (HBsAg), and antibodies to the core (anti-HBc) and antibody to the hepatitis B surface (anti-HBs) antigens. Eight hundred and twenty-two subjects were eligible for analysis consisting of 449 vaccinated and 373 controls. The prevalence of anti-HBc was 43.2% in unvaccinated children compared to 10.5% in vaccinated children (p < 0.001). The rate of HBsAg was 11.8% in the unvaccinated group and 2% in the vaccinated group (p < 0.001). The vaccine effectiveness against anti-HBc was 84.6% (95% confidence interval 77.8, 89.3%) and the effectiveness against infection was 84.7% (95% confidence interval 68.2, 92.6%). Sixty-one percent of vaccinated subjects had protective antibodies ≥ 10 EIU/ml compared to 18% of controls (p < 0.001) and the geometric mean titers (GMT) were 19.96 and 7.28 EIU/ml respectively (p < 0.001). Vaccinated subjects were protected at least for five to seven years following HB vaccination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508678     DOI: 10.4161/hv.7.6.14990

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  6 in total

1.  Levels of regulatory B cells do not predict serological responses to hepatitis B vaccine.

Authors:  Maria Bolther; Karen Lise Dahl Andersen; Martin Tolstrup; Kumar Visvanathan; Ian Woolley; Narelle Skinner; Rosemary Millen; Nadia Warner; Lars Østergaard; Søren Jensen-Fangel
Journal:  Hum Vaccin Immunother       Date:  2018-04-11       Impact factor: 3.452

2.  Hepatitis B infection among Nigerian children admitted to a children's emergency room.

Authors:  Ayebo E Sadoh; Antoinette Ofili
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

Review 3.  The status of hepatitis B control in the African region.

Authors:  Lucy Breakwell; Carol Tevi-Benissan; Lana Childs; Richard Mihigo; Rania Tohme
Journal:  Pan Afr Med J       Date:  2017-06-22

4.  Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria.

Authors:  Mary Adetola Lawal; Oluwafunmilayo Funke Adeniyi; Patricia Eyanya Akintan; Abideen Olurotimi Salako; Olorunfemi Sunday Omotosho; Edamisan Olusoji Temiye
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

5.  Immune response to hepatitis B vaccine following complete immunization of children attending two regional hospitals in the Southwest region of Cameroon: a cross sectional study.

Authors:  Ephesians N Anutebeh; Lambed Tatah; Vitalis F Feteh; Desmond Aroke; Jules C N Assob; Simeon Pierre Choukem
Journal:  BMC Infect Dis       Date:  2021-12-02       Impact factor: 3.090

6.  Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, Malawi.

Authors:  Alexander J Stockdale; James E Meiring; Isaac T Shawa; Deus Thindwa; Niza M Silungwe; Maurice Mbewe; Rabson Kachala; Benno Kreuels; Pratiksha Patel; Priyanka Patel; Marc Y R Henrion; Naor Bar-Zeev; Todd D Swarthout; Robert S Heyderman; Stephen B Gordon; Anna Maria Geretti; Melita A Gordon
Journal:  J Infect Dis       Date:  2022-09-13       Impact factor: 7.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.